Aclaris Therapeutics, Inc. (ACRS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 7M 14M 21M Q3 '21: 1.7M Q4 '21: 1.5M Q1 '22: 1.5M Q2 '22: 1.5M Q3 '22: 19M Q4 '22: 7.8M Q1 '23: 2.5M Q2 '23: 1.9M Q3 '23: 9.3M Q4 '23: 17.6M Q1 '24: 2.4M Q2 '24: 2.8M Q3 '24: 4.3M Q4 '24: 9.2M Q1 '25: 1.5M Q2 '25: 1.8M Q3 '25: 3.3M Q4 '25: 1.3M Q1 '26: 2M Q2 '26: 1.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 900K 1.8M 2.7M Q3 '17: 231K Q4 '17: 245K Q1 '18: 151K Q2 '18: 2.5M Q3 '18: 435K Q4 '18: 160K Q3 '17 Q4 '17 Q1 '18 Q2 '18 Q3 '18 Q4 '18

Operating Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -20.3M Q4 '21: -22.9M Q1 '22: -18.9M Q2 '22: -21M Q3 '22: -20.9M Q4 '22: -29.1M Q1 '23: -29.9M Q2 '23: -31.8M Q3 '23: -31.6M Q4 '23: -4M Q1 '24: -18.9M Q2 '24: -12.9M Q3 '24: -10.5M Q4 '24: -99.7M Q1 '25: -18.1M Q2 '25: -18.4M Q3 '25: -17.1M Q4 '25: -22.7M Q1 '26: -22.2M Q2 '26: -24.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -21.1M Q4 '21: -22.8M Q1 '22: -18.8M Q2 '22: -20.5M Q3 '22: -20M Q4 '22: -27.6M Q1 '23: -28.2M Q2 '23: -29.6M Q3 '23: -29.3M Q4 '23: -1.5M Q1 '24: -16.9M Q2 '24: -11M Q3 '24: -7.6M Q4 '24: -96.6M Q1 '25: -15.1M Q2 '25: -15.4M Q3 '25: -14.6M Q4 '25: -19.8M Q1 '26: -19.8M Q2 '26: -21.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 400K 800K 1.2M Q3 '21: 1.1M Q4 '21: 1.1M Q1 '22: 1.2M Q2 '22: 1.1M Q3 '22: 923K Q4 '22: 877K Q1 '23: 808K Q2 '23: 1M Q3 '23: 848K Q4 '23: 725K Q1 '24: 809K Q2 '24: 624K Q3 '24: 654K Q4 '24: 705K Q1 '25: 506K Q2 '25: 515K Q3 '25: 538K Q4 '25: 532K Q1 '26: 395K Q2 '26: 218K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-27M -18M -9M 0 9M 18M 27M Q3 '21: -10.6M Q4 '21: -17.1M Q1 '22: -21M Q2 '22: -19.7M Q3 '22: -7.8M Q4 '22: -19.1M Q1 '23: -26.4M Q2 '23: -20.7M Q3 '23: -24.6M Q4 '23: -6.8M Q1 '24: -20.8M Q2 '24: -12.3M Q3 '24: 22M Q4 '24: -8.9M Q1 '25: -13.1M Q2 '25: -10M Q3 '25: -10.9M Q4 '25: -13.1M Q1 '26: -18.1M Q2 '26: -19.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-30M -20M -10M 0 10M 20M 30M Q3 '21: -10.7M Q4 '21: -17.3M Q1 '22: -21.1M Q2 '22: -19.9M Q3 '22: -8M Q4 '22: -19.2M Q1 '23: -26.9M Q2 '23: -20.9M Q3 '23: -24.6M Q4 '23: -7.2M Q1 '24: -20.9M Q2 '24: -12.3M Q3 '24: 22M Q4 '24: -8.9M Q1 '25: -13.1M Q2 '25: -10M Q3 '25: -11M Q4 '25: -13.2M Q1 '26: -18.2M Q2 '26: -19.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '21: 50.3M Q2 '21: 54M Q3 '21: 61.2M Q1 '22: 61.4M Q2 '22: 66M Q3 '22: 66.7M Q1 '23: 66.9M Q2 '23: 70.6M Q3 '23: 70.8M Q1 '24: 71.1M Q2 '24: 71.3M Q3 '24: 71.4M Q1 '25: 122.4M Q2 '25: 122.6M Q3 '25: 122.6M Q1 '26: 128.8M Q2 '26: 142.7M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.80 -1.20 -0.60 0.00 0.60 1.20 1.80 Q3 '21: -1.56 Q4 '21: -1.63 Q1 '22: -1.37 Q2 '22: -1.34 Q3 '22: -1.29 Q4 '22: -1.33 Q1 '23: -1.44 Q2 '23: -1.55 Q3 '23: -1.66 Q4 '23: -1.27 Q1 '24: -1.09 Q2 '24: -0.82 Q3 '24: -0.52 Q4 '24: -1.71 Q1 '25: -1.59 Q2 '25: -1.57 Q3 '25: -1.58 Q4 '25: -0.53 Q1 '26: -0.56 Q2 '26: -0.58 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.